Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan

References

• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• BELANGER, P. M., LALANDE, M. and A1TTSE -GBEASSOR, A., 1983, Differential properties of the microsomal deamination and hydroxylation reactions. Research Communications in Chemical Pathology and Pharmacology, 40, 429–441.
   Google Scholar
• DIXON, R., FRENCH, S., KEMP, J., SELLERS, M. and YATES, R., 1998, The metabolism of zolmitriptan. Effects of an inducer and an inhibitor of cytochrome P450 on its pharmacokinetics in healthy volunteers. Clinical Drug Investigation, 15, 515–522.
   PubMed Web of Science ®Google Scholar
• DIXON, C. M., PARK, G. R. and TARBrr,, M. H., 1994, Characterisation of the enzyme responsible for the metabolism of sumatripan in human liver. Biochemical Pharmacology, 47, 1253–1257.
   Google Scholar
• DIXON, R. and WARRANDER, A., 1997, The clinical pharmacokinetics of zolmitriptan. Cephalalgia, 17 (suppl. 18), 15–20.
   PubMedGoogle Scholar
• FORRESTER, L. M., HENDERSON, C. J., GLANCEY, M. J., BACK, D. J., PARK, B. K., BL, S. E., KITTER1NGHAM, N. R., MCLAREN, A. W., MILES, J. S., SKETT, P. and WOLF, C. R., 1992, Relative expression of cytochrome P450 iso enzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochemical Journal, 281, 359–368.
   Google Scholar
• GOADSBY, P. J. and EVINSSON, L., 1994, Central and peripheral trigeminovascular activation in the cat is inhibited by the novel 5 HT1D agonist 311C90. Headache, 34, 394–399.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1997, Role of cytochrome P450 enzymes in drug—drug interactions. Advances in Pharmacology, 43, 7–35.
   PubMedGoogle Scholar
• HOUSTON, J. B., 1994, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology, 47, 1469–1479.
   PubMed Web of Science ®Google Scholar
• IWATSUBO, T., H1ROTA, N., 001E, T., SUZUKI, H., SHIMADA, N., CHB3A, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A. and SUGIYAMA, Y., 1997, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics, 73, 147–171.
   Google Scholar
• KALGUTKAR, A. S., CASTAGNOLI, N. and TESTA, B., 1995, Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. Medicinal Research Reviews, 15, 325–388.
   PubMed Web of Science ®Google Scholar
• KAUBE, H., HOSKIN, K. and GOADSBY, P. J., 1993, Inhibition by sumatriptan of central trigeminal neurones only after blood—brain barrier disruption. British Journal of Pharmacology, 109, 788–792.
   PubMed Web of Science ®Google Scholar
• KNODELL, R. G., BROWN, D. G., GWOZDE, G. P., BRIAN, W. R. and GUENGEIUCH, F. P., 1991, Differential inhibition of individual human liver cytochromes P450 by cimetidine. Gastroen-terology, 101, 1680–1691.
   PubMed Web of Science ®Google Scholar
• LIVINGSTON, M. G. and LrviNGsToN, H. M., 1996, Monoamine oxidase inhibitors. An update on drug interactions. Drug Safety, 14, 219–227.
   PubMedGoogle Scholar
• McKrnoP, D., 1985, Effects of phenobarbitone and 13-naphthofiavone on hepatic microsomal drug metabolising enzymes of the male beagle dog. Biochemical Pharmacology, 34, 3137-3142. McKrnoP, D., WILD, M. J., BUTTS, C. J. and SEVICOCK, C., 1998, Effects of propofol on human microsomal cytochrome P450 activities. Xenobiotka, 28, 845–853.
   Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors — evaluation of the specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• PECK, R. W., SEABER, E. J., DIXON, R., GILLOTIN C. G., WEATHERLEY, B. C., LAYTON, G. and POSNER, J., 1997, The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). British Journal of Clinical Pharmacology, 44, 595–599.
   Google Scholar
• PRESKORN, S. H., 1997, Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clinical Pharmacokinetics, 32 (suppl. 1), 1–21.
   PubMed Web of Science ®Google Scholar
• REESE, J. A. and BYARD, J. L.,1981, Isolation and culture of adult rat hepatocytes from liver biopsies. In Vitro, 17, 935–941.
   PubMedGoogle Scholar
• ROBERTS, R. K., GRICE, J., WOOD, L., PETROFE, V. and McGumE, C., 1981, Cimetidine impairs the elimination of theophylline and antipyrine. Gastroenterology, 81, 19–21.
   PubMed Web of Science ®Google Scholar
• RODRIGUES, A. D., 1994, Use of in vitro human metabolism studies in drug development: an industrial perspective. Biochemical Pharmacology, 48, 2147–2156.
   PubMed Web of Science ®Google Scholar
• ROLAN, P., 1997, Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia, 17 (suppl. 18), 21–27.
   PubMedGoogle Scholar
• SCHOENEN, J. and SAWYER, J., 1997, Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1pd,D agonist: an overview of efficacy. Cephalalgia, 17 (suppl. 18), 28–40.
   PubMedGoogle Scholar
• SEABER, E., ON, N., DIXON, R. M., GB3BENS M., LEAVENS, W. J., LIPTROT J., CHTT1TCK, G., POSNER, J., ROLAN, P. E. and PECK, R. W., 1997, The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). British Journal of Clinical Pharmacology, 43, 579–587.
   Google Scholar
• SEABER, E., ON, N., PHILLIPS, S., CHURCHUS, R., POSNER, J. and ROLAN P., 1996, The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. British Journal of Clinical Pharmacology, 41, 141–147.
   Google Scholar
• SHEVIADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 270,414–423.
   PubMed Web of Science ®Google Scholar
• Swm, D. A., CLEARY, E. W., WATKINS, S., HUFFMAN, C. S. and PoLvrtvo, W. J., 1998, Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics, 36, 301–305.
   PubMedGoogle Scholar